There are benefits for startup medical deviceand drug development companies to court regulators like the U.S. Food and Drug Administration early to ensure strong communication on what’s expected and what a comany’s product(s) can deliver. But on the other hand,there can be some unforeseen challenges as well. And of course the FDA has been known to change its mind and request more and more data.
This was one of the engaging discussions at the Greater Philadelphia Alliance of Capital and Technologies IMPACT conference convening venture and angel investors and the entrepreneurs with whom they invest.
To read the full, original article click on this link: 5 things for startups to consider as they walk tightrope towards regulatory approval | MedCity News
